Cargando…

Wild-type IDH1 inhibition enhances chemotherapy response in melanoma

BACKGROUND: Alternative treatment strategies in melanoma beyond immunotherapy and mutation-targeted therapy are urgently needed. Wild-type isocitrate dehydrogenase 1 (wtIDH1) has recently been implicated as a metabolic dependency in cancer. The enzyme protects cancer cells under metabolic stress, in...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zarei, Mehrdad, Hajihassani, Omid, Hue, Jonathan J., Graor, Hallie J., Loftus, Alexander W., Rathore, Moeez, Vaziri-Gohar, Ali, Asara, John M., Winter, Jordan M., Rothermel, Luke D.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2022
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9509573/ https://www.ncbi.nlm.nih.gov/pubmed/36153582 http://dx.doi.org/10.1186/s13046-022-02489-w

Ejemplares similares

Targeting wild-type IDH1 enhances chemosensitivity in pancreatic cancer
por: Zarei, Mehrdad, et al.
Publicado: (2023)

Increased glucose availability sensitizes pancreatic cancer to chemotherapy
por: Vaziri-Gohar, Ali, et al.
Publicado: (2023)

Limited nutrient availability in the tumor microenvironment renders pancreatic tumors sensitive to allosteric IDH1 inhibitors
por: Vaziri-Gohar, Ali, et al.
Publicado: (2022)

Corrigendum: Metabolic Dependencies in Pancreatic Cancer
por: Vaziri-Gohar, Ali, et al.
Publicado: (2019)

Metabolic Dependencies in Pancreatic Cancer
por: Vaziri-Gohar, Ali, et al.
Publicado: (2018)

Trends in Melanoma Phase 3 Clinical Trials since 2010: Is there Hope for Advanced Melanoma Therapies beyond Approved Treatment Mechanisms?
por: Kakish, Hanna H., et al.
Publicado: (2022)

Mismatch repair protein mutations in isocitrate dehydrogenase (IDH)-mutant astrocytoma and IDH-wild-type glioblastoma
por: Richardson, Timothy E, et al.
Publicado: (2023)

Immunotherapy Is Associated with a Survival Benefit in Patients Receiving Chemotherapy for Metastatic Pancreatic Cancer
por: Hue, Jonathan J., et al.
Publicado: (2021)

Deep Learning Can Differentiate IDH-Mutant from IDH-Wild GBM
por: Pasquini, Luca, et al.
Publicado: (2021)

Pharmacogenomic profiling reveals molecular features of chemotherapy resistance in IDH wild-type primary glioblastoma
por: Nam, Yoonhee, et al.
Publicado: (2023)

Requirement of Innate Immunity in Tumor-Bearing Mice Cured by Adoptive Immunotherapy Using Tumor-Draining Lymph Nodes
por: Ammori, John, et al.
Publicado: (2015)

Wild-Type IDH1 and Mutant IDH1 Opposingly Regulate Podoplanin Expression in Glioma()()
por: Sun, Chao, et al.
Publicado: (2020)

The efficacy of an unrestricted cycling ketogenic diet in preclinical models of IDH wild-type and IDH mutant glioma
por: Javier, Rodrigo, et al.
Publicado: (2022)

Transcriptional Characteristics of IDH-Wild Type Glioma Subgroups Highlight the Biological Processes Underlying Heterogeneity of IDH-Wild Type WHO Grade IV Gliomas
por: Chang, Yu-Zhou, et al.
Publicado: (2020)

Combination treatment of an IDH1 inhibitor with chemotherapy in IDH1 mutant acute myeloid leukemia
por: Gupta, Charu, et al.
Publicado: (2020)

Molecular landscape of IDH ‐wild type, pTERT ‐wild type adult glioblastomas
por: Liu, Emma Munan, et al.
Publicado: (2022)

Wild-Type IDH Enzymes as Actionable Targets for Cancer Therapy
por: Bergaggio, Elisa, et al.
Publicado: (2019)

Analyses of metastasis-associated genes in IDH wild-type glioma
por: Li, Xiaozhi, et al.
Publicado: (2020)

Molecular profile and its clinical impact of IDH1 mutated versus IDH1 wild type intrahepatic cholangiocarcinoma
por: Rimini, Margherita, et al.
Publicado: (2022)

The Impact of COVID-19 on Time-to-treatment in Pancreatic Adenocarcinoma: A Single Institutional Experience
por: Sugumar, Kavin, et al.
Publicado: (2021)

Energy Metabolism in IDH1 Wild-Type and IDH1-Mutated Glioblastoma Stem Cells: A Novel Target for Therapy?
por: van Noorden, Cornelis J.F., et al.
Publicado: (2021)

Mismatch repair–deficient glioma with spatially distinct IDH-mutant and IDH-wild type components arising in the setting of Lynch syndrome
por: Tan, Hao, et al.
Publicado: (2023)

Nuclear Receptor 4A2 (NR4A2/NURR1) Regulates Autophagy and Chemoresistance in Pancreatic Ductal Adenocarcinoma
por: Zarei, Mehrdad, et al.
Publicado: (2021)

Wild-type and mutated IDH1/2 enzymes and therapy responses
por: Molenaar, Remco J., et al.
Publicado: (2018)

GEN-10 WHOLE GENOME LANDSCAPE OF GLIOBLASTOMA, IDH-WILD TYPE
por: Nakashima, Takuma, et al.
Publicado: (2022)

Implications of Cellular Immaturity in Necrosis and Microvascularization in Glioblastomas IDH-Wild-Type
por: Orasanu, Cristian Ionut, et al.
Publicado: (2022)

Use of high throughput T cell receptor (TCR) DNA sequencing to characterize T cell infusion products and track clonal expansion in vivo
por: Strohl, Madeleine, et al.
Publicado: (2014)

The importance of time‐to‐adjuvant treatment on survival with pancreatic cancer: A systematic review and meta‐analysis
por: Sugumar, Kavin, et al.
Publicado: (2021)

Differential microglia and macrophage profiles in human IDH-mutant and -wild type glioblastoma
por: Poon, Candice C., et al.
Publicado: (2019)

Molecular profiling-based decision for targeted therapies in IDH wild-type glioblastoma
por: Kessler, Tobias, et al.
Publicado: (2020)

Correction: Wild-type and mutated IDH1/2 enzymes and therapy responses
por: Molenaar, Remco J., et al.
Publicado: (2018)

The Impact of Surgery in IDH 1 Wild Type Glioblastoma in Relation With the MGMT Deregulation
por: Marchi, Francesco, et al.
Publicado: (2020)

Surgery for IDH1/2 wild-type glioma invading the corpus callosum
por: Franco, Pamela, et al.
Publicado: (2020)

The Prognostic Value of NANO Scale Assessment in IDH-Wild-Type Glioblastoma Patients
por: Kasper, Johannes, et al.
Publicado: (2021)

Prognostic analysis and nomogram construction for older patients with IDH-wild-type glioblastoma
por: Cao, Wenjun, et al.
Publicado: (2023)

MRI-Based Radiomics Combined with Deep Learning for Distinguishing IDH-Mutant WHO Grade 4 Astrocytomas from IDH-Wild-Type Glioblastomas
por: Hosseini, Seyyed Ali, et al.
Publicado: (2023)

Knock-down of the TIM/TIPIN complex promotes apoptosis in melanoma cells
por: Chakraborty, Abhijit, et al.
Publicado: (2020)

Isocitrate dehydrogenase 1 (IDH1) mutation-specific microRNA signature predicts favorable prognosis in glioblastoma patients with IDH1 wild type
por: Wang, Zheng, et al.
Publicado: (2013)

Targetable Gene Fusions Associate With the IDH Wild-Type Astrocytic Lineage in Adult Gliomas
por: Ferguson, Sherise D, et al.
Publicado: (2018)

Whole genome duplication is an early event leading to aneuploidy in IDH-wild type glioblastoma
por: Boisselier, Blandine, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_38i26rdf84aqpknc85bf525au4